Examples of using Glivec in English and their translations into Hungarian
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Programming
-
Official/political
-
Computer
Glivec will only be prescribed to you by a doctor with experience in medicines to treat blood cancers or solid tumours.
If you forget to take Glivec Take the missed dose as soon as you remember on the day you missed,
What Glivec looks like and contents of the pack Glivec 100 mg capsules are orange to greyish-orange
In February, drug company Novartis averted a compulsory license on its leukemia drug Glivec by agreeing to provide it to hundreds of Thai patients for free.
The other study compared Glivec with placebo(a dummy treatment)
For adult patients with relapsed or refractory Ph+ALL Glivec monotherapy at 600 mg/day is safe,
Stop Glivec until ANC 1.5 x 109/l and platelets 75 x 109/l.
There have been post-marketing reports of spontaneous abortions and infant congenital anomalies from women who have taken Glivec.
Glivec is given by mouth with a meal
In Ph+ ALL patients, there is clinical experience of co-administering Glivec with chemotherapy(see section 5.1), but drug-drug interactions between imatinib and chemotherapy regimens are not well characterised.
Therefore, caution is recommended when administering Glivec with CYP3A4 substrates with a narrow therapeutic window(e.g. cyclosporine,
Glivec has been examined in 4 main studies involving 2133 adults and one study of 54 children with CML.
of progression to accelerated phase or blast crisis at 84 months was significantly higher in the Glivec arm compared to the IFN arm92.5% versus 85.1%.
stop Glivec until ANC 1 x 109/l and platelets.
The duration of Glivec therapy can vary with the treatment programme selected, but generally longer exposures to Glivec have yielded better results.
Do not take Glivec: if you are allergic to imatinib
These included a study involving 1106 adults that compared Glivec with the combination of interferon-alpha
Because Imatinib Actavis is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Glivec.
The estimated rate of progression-free survival at 60 months was 83.2% in the Glivec arm and 64.1% in the control arm(p< 0.001).
In patients with CML, 15.6% of the patients taking Glivec had progressed after 5 years, compared to 28.0%